•HR 1926 EH1S
retail value of drugs sold in the United
States; and
‘‘(D) determination of the status of drug
treatment in the United States, by assessing—
‘‘(i) public and private treatment ca-
pacity within each State, including infor-
mation on the number of treatment slots
available in relation to the number actually
used, including data on intravenous drug
users and pregnant women;
‘‘(ii) the extent, within each State, to
which treatment is available, on demand,
to intravenous drug users and pregnant
women;
‘‘(iii) the number of drug users the
Director estimates could benefit from
treatment; and
‘‘(iv) the success of drug treatment
programs, including an assessment of the
effectiveness of the mechanisms in place
federally, and within each State, to deter-
mine the relative quality of substance
abuse treatment programs, the qualifica-
tions of treatment personnel, and the
mechanism by which patients are admitted
•HR 1926 EH1S
to the most appropriate and cost effective
treatment setting.
‘‘(5) The Director shall include with the Na-
tional Drug Control Strategy required to be submit-
ted not later than February 1, 1994, and with every
second such strategy submitted thereafter—
‘‘(A) an assessment of the quality of cur-
rent drug use measurement instruments and
techniques to measure supply reduction and de-
mand reduction activities;
‘‘(B) an assessment of the adequacy of the
coverage of existing national drug use measure-
ment instruments and techniques to measure
the casual drug user population and groups at-
risk for drug use;
‘‘(C) an assessment of the actions the Di-
rector shall take to correct any deficiencies and
limitations identified pursuant to subpara-
graphs (A) and (B); and
‘‘(D) identification of the specific factors
that restrict the availability of treatment serv-
ices to those seeking it and proposed adminis-
trative or legislative remedies to make treat-
ment available to those individuals.
•HR 1926 EH1S
‘‘(6) Federal agencies responsible for the collec-
tion or estimation of drug-related information re-
quired by the Director shall cooperate with the Di-
rector, to the fullest extent possible, to enable the
Director to satisfy the requirements of sections 4
and 5.
‘‘(7) By June 1, 1994, and with each National
Drug Control Strategy submitted thereafter, the Di-
rector shall report to the President and the Congress
on the Director’s assessment of drug use and avail-
ability in the United States, including an estimate of
the effectiveness of interdiction, treatment, preven-
tion, law enforcement, and international programs
under the National Drug Control Strategy in effect
in the preceding year in reducing drug use and
availability.’’.
SEC. 5. DIRECTOR AS A MEMBER OF THE NATIONAL SECU-
RITY COUNCIL.
Section 402(a)(7) of title 50, United States Code, is
amended by—
(1) striking ‘‘and’’ after the semicolon in para-
graph (6);
(2) redesignating paragraph (7) as paragraph
(8); and
(3) inserting after paragraph (6) the following:
•HR 1926 EH1S
‘‘(7) the Director of the Office of National
Drug Control Policy; and’’.
SEC. 6. COUNTER-DRUG TECHNOLOGY ASSESSMENT CEN-
TER.
(a) DRUG ABUSE ADDICTION AND REHABILITATION
CENTER.—Section 1003A of the National Narcotics Lead-
ership Act of 1988 (21 U.S.C. 1502a(c)(1)) is amended—
(1) by redesignating subparagraphs (B), (C),
and (D) as subparagraphs (C), (D), and (E), respec-
tively; and
(2) by inserting after subparagraph (A) the fol-
lowing:
‘‘(B) identify and support, through inter-
agency agreements or grants that are subjected
to peer review by independent advisory boards,
the application of technology to expanding the
effectiveness or availability of drug treatment;’’.
(b) ASSISTANCE FROM THE ADVANCED RESEARCH
PROJECT AGENCY.—Section 1003A of the National Nar-
cotics Leadership Act of 1988 (21 U.S.C. 1502a) is
amended by adding at the end the following:
‘‘(f) ASSISTANCE AND SUPPORT TO OFFICE OF NA-
TIONAL DRUG CONTROL POLICY.—The Director of the
Advanced Research Project Agency shall, to the fullest ex-
•HR 1926 EH1S
tent possible, render assistance and support to the Office
of National Drug Control Policy and its Director.’’.
(c) REPEAL
AND REDESIGNATION.—The National
Narcotics Leadership Act of 1988 is amended by—
(1) repealing section 1008 (21 U.S.C. 1505), as
in effect on the date of the enactment of this Act;
(2) redesignating section 1003A, as amended by
subsection (b) of this section, as section 1008; and
(3) moving such section, as redesignated, so as
to follow section 1007.
SEC. 7. PAYING CERTAIN NECESSARY EXPENSES FOR
STRATEGY CONSULTATION.
Section 1005(a)(3) of the National Narcotics Leader-
ship Act of 1988 (21 U.S.C. 1504(a)(3)) is amended by
adding at the end the following:
‘‘(C) The Director may pay for the necessary and ap-
propriate expenses for assemblages of individuals provid-
ing consultation to the Director in developing the National
Drug Control Strategy.’’.
SEC. 8. AUTHORIZATION OF APPROPRIATIONS.
Section 1011 of the National Narcotics Leadership
Act of 1988 (21 U.S.C. 1508) is amended by striking
‘‘$3,500,000’’ and all that follows through ‘‘years,’’ and
inserting ‘‘such sums as may be necessary for fiscal year
1994,’’.
•HR 1926 EH1S
SEC. 9. TERMINATION OF OFFICE OF NATIONAL DRUG CON-
TROL POLICY.
Section 1009 of the National Narcotics Leadership
Act of 1988 (21 U.S.C. 1506) is amended by striking ‘‘the
date which is 5 years after the date of the enactment of
this subtitle’’ and inserting ‘‘September 30, 1994’’.
Passed the House of Representatives November 21,
1993.
Attest:
Clerk.